Pelvic Health Module
BehavioralTelerehabilitation program involving pelvic floor exercises, education and counselling.
NCT Number: NCT06822582
The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
University of Alberta, Edmonton, Alberta, Canada
The GYVE study aims at testing a new online program (eModule) designed to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues such as urinary incontinence and pain during sex. These cancers are common and can cause pelvic health problems due to treatments like surgery, radiation, and hormone therapy. Many people treated for these cancers experience issues that affect their daily lives and quality of life. Physiotherapy for pelvic health can help, but access to these services is often limited due to costs, travel, and other barriers. The study's goals are to see if the new eModule is practical and well-received by participants and to check if it helps reduce pelvic health problems. More specifically, this study aims to:
Obj 1) Evaluate the feasibility and the acceptability of implementing the new eModule, as perceived by people treated for breast or gynecological cancer.
Obj 2) Explore the preliminary effectiveness of the new eModule in reducing urogenital impairments.
The hypothesis is that the eModule will be practical and well-liked, with at least 70% of participants completing the study and over 85% reporting high satisfaction. The study will be conducted in Quebec and Edmonton with 20 participants who have had breast or gynecologic cancer and are experiencing pelvic health issues. The eModule will last 12 weeks and include weekly online group sessions led by a physiotherapist, covering topics like pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Participants will complete questionnaires before, during, and after the program to measure its impact. Outcomes measured will include feasibility (session attendance and study completion), acceptability (participant satisfaction), and effectiveness (changes in pelvic health issues). The study will follow ethical guidelines to protect participants' privacy and ensure their informed consent.
The study is led by experts in cancer rehabilitation and pelvic health from various Canadian institutions and will take place over several months, with phases for preparation, recruitment, intervention, data collection, and analysis. If successful, this study will provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to larger studies and broader implementation to help more people with lived experience of cancer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Telerehabilitation program involving pelvic floor exercises, education and counselling.
Time frame: From enrollment to the end of intervention at 12 weeks
The Patient Global Impression of Change scale will be used to determine the extent to which the intervention is perceived as likely to remedy urogenital deficiencies.
Time frame: From enrollment to the end of intervention at 12 weeks
number of intervention sessions attended/participant
Time frame: From enrollment to the end of intervention at 12 weeks
number of participants who did not complete participation / those who did.
Time frame: From enrollment to the end of intervention at 12 weeks
a modular questionnaire for urinary symptoms (12 items) and bowel symptoms (20 items).
Time frame: From enrollment to the end of intervention at 12 weeks
a 38-item questionnaire to assess vulvar pain intensity
Time frame: From enrollment to the end of intervention at 12 weeks
a 19-item multidimensional questionnaire to assess six domains of sexual functioning: desire, arousal, lubrication, orgasm, satisfaction, and pain.
Time frame: From enrollment to the end of intervention at 12 weeks
modified from the self-efficacy for chronic disease management questionnaire, a 6-item survey to determine a person's perceived overall ability to cope with symptoms in various challenging or stressful situations.
Time frame: From enrollment to the end of intervention at 12 weeks
questions developed in connection with program acceptability (Relevance of content, Perceived burden, Appropriateness of intervention and sense of safety, Usability, Geographical accessibility, Satisfaction with ease of access to intervention, Previous access to services, Barriers, and Perceived best time in cancer care trajectory)
Contact information is provided by the study sponsor or research team.
Clémence Bélanger, M.Sc. PT
CONTACT
418-529-9141 ext. 46115
Stéphanie Bernard, Ph.D. PT
CONTACT
418-529-9141 ext. 46115
Laval University
Other
A Pelvic Health eModule to Address Urogenital Impairments After Breast and Gynecologic Cancer: a Pilot Prospective Interventional Study
Acronym: GYVE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735962
Gynecologic Cancers, Infections
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07216456
Anorectal Cancer, Female Urogenital Diseases
Durham, North Carolina, United States
View Trial DetailsNCT07055854
Breast Cancer, Breast Diseases
Corvallis, Oregon, United States
View Trial DetailsNCT07313839
Gynecologic Cancers, Pathologic Processes
Parma, Italy
View Trial Details